Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Potent efficacy in vivo of Merck's novel glucagon receptor antagonists

Sep. 22, 2006

GSK reports on new MCHR1 antagonists for the treatment of obesity

Sep. 22, 2006

Exenatide gains positive European opinion for the treatment of type 2 diabetes

Sep. 22, 2006

Novel treatment option for lipoprotein disorders jointly reported by Negma-Lerads and CNRS

Sep. 22, 2006

Recent patents describe new treatment options for endocrine-related disorders

Sep. 21, 2006

Alexion seeks U.S. approval for treatment of rare genetic blood disorder

Sep. 21, 2006

Nastech's intranasal insulin begins phase I clinical evaluation

Sep. 21, 2006

Polyphenolic extract from red grapes beneficial for metabolic syndrome

Sep. 21, 2006

Snapshots on antidiabetic drug candidates in clinical development

Sep. 21, 2006

The VEGF antagonist bevacizumab shows promise in HHT: News in Context

Sep. 20, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...